Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 30 Aug 2009):

Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms?

Full Abstract

This study aimed to determine the influence of autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen (HLA) class II genes on age at chronic fatigue syndrome (CFS) onset and symptoms. Eighty-one CFS patients were enrolled, and clinical data were recorded. Autoantibodies to different components of the central nervous system were tested. Polymorphisms in the promoter of the serotonin transporter gene (l/s) and a single nucleotide polymorphism in the serotonin receptor-2A gene (A/G) as well as HLA class II alleles were determined. Multivariate logistic-regression analyses were carried out. The mean age at CFS onset +/- SD was 33.5 +/- 12.5 years. An age at CFS onset (ACFSO) during the third decade of life was associated with the serotonin receptor AA genotype and the HLA-DRB1*03 allele. An ACFSO during the fourth decade of life was associated with the HLA-DRB1*07 allele, whereas an ACFSO > or = 43 years was associated with having at least one copy of the serotonin G allele. Concerning CFS symptoms, the serotonin AG genotype was protective against depressive symptoms. Although having at least one copy of the serotonin A allele and being female were associated with risk for arthralgia, the presence of antineuronal cell antibodies was protective against this. Episodes of unexplained fever were associated with the HLA-DRB1*11 allele. None of the genetic or serological features was associated with myalgia. None of the antibodies determined correlated with any ACFSO or other symptoms. Our results reveal that in CFS, like other autoimmune diseases, different genetic features are related to age at CFS onset and symptoms.

 

Author information

Author/s: Ortega-Hernandez, Oscar-Danilo (OD); Cuccia, Mariaclara (M); Bozzini, Sara (S); Bassi, Nicola (N); Moscavitch, Samuel (S); Diaz-Gallo, Lina-Marcela (LM); Blank, Miri (M); Agmon-Levin, Nancy (N); Shoenfeld, Yehuda (Y);

Affiliation: Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci), published in United States. (Language: eng)

Reference: 2009-Sep; vol 1173 (issue ) : pp 589-99

Dates: Created 2009/09/17; Completed 2009/10/29;

PMID: 19758204, status: MEDLINE (last retrieval date: 10/29/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: Autoantibodies (0) ; HLA-DR Antigens (0) ; Receptor, Serotonin, 5-HT2A (0) ; Serotonin Plasma Membrane Transport Proteins (0) ; HLA-DRB1 antigen (128338-86-3)

Related articles

These are the highest related articles currently in the database:

See 100+ related articles.

Related Article Map

7/30/2005
3/11/2008
Higher Relevance Score (100)
Lower Relevance Score (57)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.

© Advanogy LLC 2003-2009 - All rights reserved. Terms of Use | Contact Us | Index